Clairity raised $43 million to expand its AI mammography tool for predicting five-year breast cancer risk.
Key Details
- 1Clairity, founded in 2020 by Dr. Constance Lehman of Mass General, focuses on AI for breast cancer risk assessment.
- 2The company secured $43 million in Series B funding led by Ace Global Equity and Santé Ventures, with support from the Breast Cancer Research Foundation.
- 3Clairity Breast is the first AI tool to predict five-year breast cancer risk from standard mammograms.
- 4The product received FDA de novo authorization in May 2024.
- 5New funds will support commercialization and partnership expansion.
Why It Matters
Clairity's advancements could lead to earlier detection and prevention strategies using existing mammography infrastructure, potentially improving patient outcomes. The funding and FDA approval mark important milestones for AI adoption in radiology.
Source
Radiology Business
Related News
•Radiology Business
a2z Radiology Raises $5M, Lands FDA Clearance for Multi-Condition CT AI
Boston-based a2z Radiology raised $4.5M and earned FDA clearance for its Unified Triage AI solution for abdominal and pelvic CT scans.
•AuntMinnie
AI Ultrasound Tool May Cut Unnecessary Breast Biopsies by 60%
An FDA-cleared AI tool for breast ultrasound may reduce unnecessary biopsies of benign breast lesions by about 60%.
•AuntMinnie
AI Model Using Mammograms Enhances Five-Year Breast Cancer Risk Assessment
A new image-only AI model more accurately predicts five-year breast cancer risk than breast density alone, according to multinational research presented at RSNA 2025.